About Protalix Biotherapeutics (NYSEAMERICAN:PLX)
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSEAMERICAN:PLX
CUSIPN/A
Phone+972-4-9028100
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares145,570,000
Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions
What is Protalix Biotherapeutics' stock symbol?
Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."
How were Protalix Biotherapeutics' earnings last quarter?
Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) issued its quarterly earnings data on Tuesday, March, 6th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.04. The business had revenue of $2.47 million for the quarter, compared to analyst estimates of $9.70 million. View Protalix Biotherapeutics' Earnings History.
What price target have analysts set for PLX?
2 brokers have issued 1-year price targets for Protalix Biotherapeutics' shares. Their predictions range from $5.00 to $5.00. On average, they anticipate Protalix Biotherapeutics' stock price to reach $5.00 in the next twelve months. View Analyst Ratings for Protalix Biotherapeutics.
Are investors shorting Protalix Biotherapeutics?
Protalix Biotherapeutics saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 5,208,192 shares, an increase of 10.1% from the March 30th total of 4,728,669 shares. Based on an average trading volume of 858,309 shares, the short-interest ratio is currently 6.1 days. Currently, 3.8% of the company's stock are sold short.
Who are Protalix Biotherapeutics' key executives?
Protalix Biotherapeutics' management team includes the folowing people:
- Shlomo Yanai, Chairman of the Board (Age 64)
- Moshe Manor, President, Chief Executive Officer, Director (Age 60)
- Yossi Maimon CPA, Chief Financial Officer, Vice President, Treasurer, Secretary (Age 46)
- Tzvi Palash, Chief Operating Officer (Age 60)
- Yoseph Shaaltiel Ph.D., Executive Vice President - Research & Development (Age 63)
- Einat Brill Almon Ph.D., Senior Vice President - Product Development (Age 57)
- Amos Bar-Shalev, Independent Director (Age 64)
- Zeev Bronfeld, Independent Director (Age 66)
- Yodfat Harel Buchris, Independent Director (Age 45)
- Roger D. Kornberg Ph.D., Independent Director (Age 69)
Has Protalix Biotherapeutics been receiving favorable news coverage?
Headlines about PLX stock have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Protalix Biotherapeutics earned a coverage optimism score of 0.01 on Accern's scale. They also assigned media coverage about the company an impact score of 45.02 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Protalix Biotherapeutics?
Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protalix Biotherapeutics' stock price today?
One share of PLX stock can currently be purchased for approximately $0.43.
How big of a company is Protalix Biotherapeutics?
Protalix Biotherapeutics has a market capitalization of $308.37 million.
How can I contact Protalix Biotherapeutics?
Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.
MarketBeat Community Rating for Protalix Biotherapeutics (PLX)
MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe PLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Protalix Biotherapeutics (NYSEAMERICAN:PLX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Protalix Biotherapeutics in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 1,062.79%. The high price target for PLX is $5.00 and the low price target for PLX is $5.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.00 | $5.00 | $5.00 | $3.6667 |
| Price Target Upside: | 1,062.79% upside | 681.25% upside | 604.23% upside | 491.40% upside |
Protalix Biotherapeutics (NYSEAMERICAN:PLX) Consensus Price Target History
Protalix Biotherapeutics (NYSEAMERICAN:PLX) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Protalix Biotherapeutics (NYSEAMERICAN:PLX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Protalix Biotherapeutics (NYSEAMERICAN PLX) Insider Trading and Institutional Ownership History
Protalix Biotherapeutics (NYSEAMERICAN PLX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/1/2017 | Steve Dabner | Director | Buy | 6,000 | $0.32 | $1,920.00 | | |
| 8/31/2017 | Steve Dabner | Director | Buy | 10,000 | $0.33 | $3,300.00 | | |
| 7/28/2017 | Steve Dabner | Director | Buy | 500 | $0.36 | $180.00 | | |
| 7/26/2017 | Steve Dabner | Director | Buy | 3,500 | $0.35 | $1,225.00 | | |
| 7/25/2017 | Steve Dabner | Director | Buy | 10,000 | $0.35 | $3,500.00 | | |
| 6/2/2017 | Randall Peel Boyd | Insider | Buy | 38,300 | $0.47 | $18,001.00 | | |
| 5/16/2017 | Moshe Manor | CEO | Buy | 50,000 | $0.81 | $40,500.00 | 50,000 |  |
| 1/27/2017 | Terence Stanley Meek | Director | Buy | 12,000 | $0.42 | $5,040.00 | | |
| 1/25/2017 | Madalena Energy Inc. | Insider | Sell | 190,500 | $0.38 | $72,390.00 | | |
| 1/23/2017 | Madalena Energy Inc. | Insider | Sell | 500 | $0.39 | $195.00 | | |
| 1/12/2017 | Madalena Energy Inc. | Insider | Sell | 54,000 | $0.42 | $22,680.00 | | |
| 1/11/2017 | Madalena Energy Inc. | Insider | Sell | 51,000 | $0.44 | $22,440.00 | | |
| 12/2/2016 | Camber Capital Management Llc | Major Shareholder | Sell | 2,500,000 | $0.32 | $800,000.00 | | |
| 12/14/2015 | Yossi Maimon | CFO | Buy | 10,000 | $0.78 | $7,800.00 | 10,000 | |
| 10/19/2015 | Camber Capital Management Llc | Major Shareholder | Buy | 4,000,423 | $1.00 | $4,000,423.00 | | |
| 8/15/2013 | Alfred Akirov | Director | Sell | 112,330 | $5.05 | $567,266.50 | | |
(Data available from 1/1/2013 forward)
Protalix Biotherapeutics (NYSEAMERICAN PLX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Protalix Biotherapeutics Inc (PLX) Short Interest Update
www.americanbankingnews.com - April 24 at 7:00 PM |
| Protalix Biotherapeutics (PLX) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 7:31 PM |
| Zacks Investment Research Lowers Protalix Biotherapeutics (PLX) to Hold
www.americanbankingnews.com - April 17 at 8:43 PM |
| Short Interest in Protalix Biotherapeutics Inc (PLX) Drops By 0.8%
www.americanbankingnews.com - April 11 at 2:50 AM |
| Protalix Biotherapeutics (PLX) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - April 10 at 11:38 PM |
| Zacks Investment Research Upgrades Protalix Biotherapeutics (PLX) to "Buy"
www.americanbankingnews.com - April 5 at 11:19 PM |
| Protalix Biotherapeutics (PLX) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - March 31 at 5:28 PM |
| HC Wainwright Analysts Give Protalix Biotherapeutics (PLX) a $5.00 Price Target
www.americanbankingnews.com - March 30 at 3:58 PM |
| Protalix Biotherapeutics (PLX) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - March 29 at 5:48 PM |
 | Research Report Identifies Comtech Telecommunications, Protalix BioTherapeutics, Kraton, ABB, Cheniere Energy Partners LP, and Heidrick & Struggles International with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
finance.yahoo.com - March 28 at 8:28 AM |
| Short Interest in Protalix Biotherapeutics Inc (PLX) Expands By 0.2%
www.americanbankingnews.com - March 28 at 1:40 AM |
 | Protalix BioTherapeutics (PLX) Presents At BioCentury's 25th Annual Future Leaders In The Biotech Industry Conference - Slideshow
seekingalpha.com - March 27 at 5:13 PM |
| Protalix BioTherapeutics, OPRX-106 Phase II Results, Analysts Review and Target, Catalysts
finance.yahoo.com - March 20 at 8:29 AM |
 | Protalix BioTherapeutics Announces Acceptance of Abstract on OPRX-106 as a Lecture Presentation at the Digestive ... - GlobeNewswire (press release)
globenewswire.com - March 19 at 8:23 AM |
| Protalix BioTherapeutics Announces Acceptance of Abstract on OPRX-106 as a Lecture Presentation at the Digestive Diseases Week® 2018
finance.yahoo.com - March 19 at 8:23 AM |
| Jefferies Group Comments on Protalix Biotherapeutics Inc's Q1 2018 Earnings (PLX)
www.americanbankingnews.com - March 16 at 8:10 AM |
| Protalix Biotherapeutics Inc Forecasted to Post FY2022 Earnings of $0.36 Per Share (PLX)
www.americanbankingnews.com - March 15 at 2:52 PM |
| Protalix: It's Time To Sell - Seeking Alpha
seekingalpha.com - March 15 at 8:17 AM |
| Protalix BioTherapeutics to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference
finance.yahoo.com - March 15 at 8:17 AM |
 | Protalix BioTherapeutics (PLX) Reports Positive Results from Phase II Clinical Trial of OPRX-106 - StreetInsider.com
www.streetinsider.com - March 14 at 8:34 AM |
| Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis
finance.yahoo.com - March 13 at 8:26 AM |
| Protalix Biotherapeutics (PLX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 10 at 6:06 AM |
| Protalix Biotherapeutics Inc (PLX) Short Interest Down 1.9% in February
www.americanbankingnews.com - March 10 at 1:47 AM |
| Protalix Biotherapeutics (PLX) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - March 7 at 11:50 AM |
| Protalix BioTherapeutics' (PLX) CEO Moshe Manor on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 7 at 8:19 AM |
| Protalix Biotherapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 6 at 8:16 AM |
| Protalix BioTherapeutics Inc (NYSEMKT:PLX): Are Analysts Optimistic?
finance.yahoo.com - March 6 at 8:16 AM |
| Protalix BioTherapeutics Reports 2017 Full Year Results and Provides Corporate Update
finance.yahoo.com - March 6 at 8:16 AM |
| Protalix Biotherapeutics (PLX) to Release Earnings on Tuesday
www.americanbankingnews.com - February 27 at 8:18 PM |
| Protalix BioTherapeutics to Hold Full-Year 2017 Financial Results and Corporate Update Conference Call on March 6 ... - GlobeNewswire (press release)
globenewswire.com - February 27 at 8:19 AM |
| Protalix BioTherapeutics to Hold Full-Year 2017 Financial Results and Corporate Update Conference Call on March 6, 2018
finance.yahoo.com - February 26 at 8:17 AM |
| Protalix BioTherapeutics (PLX) Reports Final Dosing of Last Patient ... - StreetInsider.com
www.streetinsider.com - February 16 at 8:18 AM |
| Protalix BioTherapeutics Announces Final Dosing of Last Patient in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
finance.yahoo.com - February 15 at 9:19 AM |
| Protalix Biotherapeutics (PLX) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - February 12 at 6:34 PM |
| Short Interest in Protalix Biotherapeutics Inc (PLX) Rises By 16.6%
www.americanbankingnews.com - February 9 at 8:28 PM |
| Protalix Biotherapeutics (PLX) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - February 1 at 1:52 PM |
| Protalix BioTherapeutics’ pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration
finance.yahoo.com - January 31 at 9:46 AM |
| Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium™ 2018
finance.yahoo.com - January 29 at 9:43 AM |
| Short Interest in Protalix Biotherapeutics Inc (PLX) Grows By 49.7%
www.americanbankingnews.com - January 24 at 5:40 PM |
 | 28 Stocks Moving In Tuesday's Mid-Day Session - Benzinga
www.benzinga.com - January 3 at 9:34 AM |
 | Protalix Reports Positive Interim Data From Phase II Clinical Trial Of OPRX-106
www.nasdaq.com - January 2 at 10:03 AM |
| Protalix BioTherapeutics Reports Positive Interim Data from Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
finance.yahoo.com - January 2 at 10:03 AM |
| Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Fly 10% After Market Gets Word of Impressive Phase II Interim Data in UC
finance.yahoo.com - January 2 at 10:03 AM |
| Wired News - Protalix BioTherapeutics Granted Orphan Drug Designation for the Treatment of Fabry Disease
finance.yahoo.com - December 29 at 9:14 AM |
| Protalix (PLX) Fabry Disease Candidate Gets Orphan Status - Nasdaq
www.nasdaq.com - December 28 at 4:40 PM |
| Protalix Biotherapeutics Inc (PLX) Sees Large Decline in Short Interest
www.americanbankingnews.com - December 28 at 2:09 AM |
| Protalix BioTherapeutics (PLX) Granted Orphan Drug Designation on PRX-102 by the European Commission - StreetInsider.com
www.streetinsider.com - December 27 at 7:48 PM |
| Protalix BioTherapeutics (PLX) Granted Orphan Drug Designation on PRX-102 by the European Commission
www.streetinsider.com - December 27 at 6:54 PM |
| Pre-Open Movers 12/27: (WATT) (HTGM) (NVFY) Higher; (ELY) (TSLA) Lower (more...)
www.streetinsider.com - December 27 at 1:54 PM |
| Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
www.nasdaq.com - December 27 at 1:54 PM |
Protalix Biotherapeutics (NYSEAMERICAN:PLX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Protalix Biotherapeutics (NYSEAMERICAN:PLX) Income Statement, Balance Sheet and Cash Flow Statement
Protalix Biotherapeutics (NYSEAMERICAN PLX) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
